CR20110698A - Proceso para la producción de derivados de amina ópticamente activos (divisional exp. n° 8975) - Google Patents

Proceso para la producción de derivados de amina ópticamente activos (divisional exp. n° 8975)

Info

Publication number
CR20110698A
CR20110698A CR20110698A CR20110698A CR20110698A CR 20110698 A CR20110698 A CR 20110698A CR 20110698 A CR20110698 A CR 20110698A CR 20110698 A CR20110698 A CR 20110698A CR 20110698 A CR20110698 A CR 20110698A
Authority
CR
Costa Rica
Prior art keywords
derivatives
amina
divisional
exp
production
Prior art date
Application number
CR20110698A
Other languages
English (en)
Inventor
Shinichi Urayama
Eigo Mutou
Atsushi Inagaki
Takashi Okada
Shigeharu Sugisaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36059992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110698(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR20110698A publication Critical patent/CR20110698A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Un proceso industrial para producir derivados de amina ópticamente activo de alta pureza en alto rendimiento mientras se inhibe la formación de productos secundarios, por medio de dos fases.
CR20110698A 2004-09-13 2011-12-21 Proceso para la producción de derivados de amina ópticamente activos (divisional exp. n° 8975) CR20110698A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004265307 2004-09-13

Publications (1)

Publication Number Publication Date
CR20110698A true CR20110698A (es) 2012-03-08

Family

ID=36059992

Family Applications (2)

Application Number Title Priority Date Filing Date
CR8975A CR8975A (es) 2004-09-13 2007-03-06 Proceso para la produccion de derivados de amina opticamente activos
CR20110698A CR20110698A (es) 2004-09-13 2011-12-21 Proceso para la producción de derivados de amina ópticamente activos (divisional exp. n° 8975)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR8975A CR8975A (es) 2004-09-13 2007-03-06 Proceso para la produccion de derivados de amina opticamente activos

Country Status (32)

Country Link
US (4) US8097737B2 (es)
EP (2) EP1792899B1 (es)
JP (2) JP5127228B2 (es)
KR (1) KR101298335B1 (es)
CN (2) CN102516211A (es)
AR (1) AR050737A1 (es)
AU (1) AU2005283521B2 (es)
BR (1) BRPI0515170A (es)
CA (2) CA2579121C (es)
CR (2) CR8975A (es)
EC (1) ECSP077317A (es)
ES (1) ES2485890T3 (es)
GE (1) GEP20094725B (es)
GT (2) GT200500257A (es)
HN (1) HN2005000548A (es)
IL (2) IL181462A (es)
MA (1) MA28855B1 (es)
MX (1) MX2007002822A (es)
MY (2) MY158073A (es)
NO (1) NO20071866L (es)
NZ (1) NZ553562A (es)
PA (1) PA8645701A1 (es)
PE (3) PE20060662A1 (es)
PH (1) PH12012501172A1 (es)
RU (1) RU2385318C2 (es)
SA (1) SA05260347A (es)
SG (1) SG151330A1 (es)
TW (1) TWI400220B (es)
UA (1) UA95598C2 (es)
UY (1) UY29118A1 (es)
WO (1) WO2006030739A1 (es)
ZA (1) ZA200701724B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008123067A1 (ja) * 2007-03-19 2008-10-16 Takeda Pharmaceutical Company Limited アリルアミン不斉水素化法
WO2008150953A1 (en) * 2007-05-30 2008-12-11 Dr. Reddy's Laboratories Ltd. Process of making ramelteon and related substances
US8084630B2 (en) 2007-05-31 2011-12-27 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
US20090105490A1 (en) * 2007-07-12 2009-04-23 Nurit Perlman Polymorphic forms of ramelteon and processes for preparation thereof
CN101531647B (zh) * 2008-03-13 2012-10-31 常州亚邦制药有限公司 (±)-2-(1,6,7,8-四氢-2H-茚并[5,4-b]呋喃-8-基)乙胺的拆分方法
WO2010007022A1 (en) * 2008-07-14 2010-01-21 Lek Pharmaceuticals D.D. Synthesis of 6,7-dihydro-1h-indeno[5,4-b]furan-8(2h)-one as intermediate in the preparation of ramelteon
US20100152468A1 (en) * 2008-10-16 2010-06-17 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
EP2396309A1 (en) 2009-02-12 2011-12-21 LEK Pharmaceuticals d.d. Synthesis of (s)-n-ý2-(1,6,7,8-tetrahydro-2h-indeno-ý5,4-b¨furan-8-yl)ethyl¨propionamide
CN101824012B (zh) * 2009-03-02 2011-12-07 四川大学 2-(1,6,7,8-四氢-2H-茚并-[5,4-b]呋喃-8-基)乙腈及其制备方法和用途
EP2406242B1 (en) 2009-03-10 2013-06-05 Industriale Chimica S.R.L. Process for the preparation of ramelteon
EP2243775A1 (en) 2009-04-07 2010-10-27 LEK Pharmaceuticals d.d. Synthesis of 1-(2,3-Dihydrobenzofuran-4-YL)ethanone as intermediate in the preparation of ramelteon
WO2011027319A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Process for the preparation of an intermediate for ramelteon
WO2011027323A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Process for the preparation of ramelteon
CN101648931B (zh) * 2009-09-21 2012-05-09 四川大学 一种3-(2,3-二氢苯并呋喃-5-基)-丙酸的制备方法
CN101665477B (zh) * 2009-09-21 2012-05-09 四川大学 (e)-3-(苯并呋喃-5-基)丙烯酸酯类化合物、其制备方法和用途
WO2011044990A1 (en) 2009-09-29 2011-04-21 Lonza Ltd Process for preparing 1,2,6,7-tetrahydro-8h-indeno[5,4-b]furan-8-one
WO2012035303A2 (en) 2010-09-17 2012-03-22 Cipla Limited Et Al A novel process for synthesis of ramelteon, and key intermediates for the synthesis of ramelteon
CN103664849B (zh) * 2012-08-31 2017-03-29 上海阳帆医药科技有限公司 制备2‑(1,6,7,8‑四氢‑2H‑茚并[5,4‑b]呋喃‑8‑亚基乙胺的方法
CN102924410A (zh) * 2012-10-29 2013-02-13 华润赛科药业有限责任公司 一种雷美替胺的制备方法及其中间体
CN103396387A (zh) * 2013-08-07 2013-11-20 安徽联创药物化学有限公司 雷美替胺中间体的制备方法
CN105277628B (zh) * 2014-07-07 2017-05-31 南京长澳医药科技有限公司 通过高效液相色谱法分离测定雷美替胺及其杂质的方法
CN104402848B (zh) * 2014-09-22 2017-02-08 珠海联邦制药股份有限公司 雷美替胺中的杂质化合物的制备方法及制备的标准品
CN105622557B (zh) * 2014-11-05 2018-12-04 上海医药工业研究院 雷美替胺中间体及其制备方法
KR102359229B1 (ko) 2020-04-16 2022-02-07 제이투에이치바이오텍 (주) 라멜테온의 제조 방법 및 이러한 제조 방법에 이용되는 중간체 화합물
CN115477628A (zh) * 2022-10-17 2022-12-16 江苏海悦康医药科技有限公司 一种雷美替胺二聚体的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0757758B2 (ja) 1988-10-24 1995-06-21 高砂香料工業株式会社 ルテニウム―ホスフィン錯体
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
EP0812835B1 (en) 1995-03-02 2001-05-23 Sankyo Company Limited Optically active thiazolidinone derivatives
EP1199304A1 (en) * 1997-03-05 2002-04-24 Takeda Chemical Industries, Ltd. Bicyclic compounds and pharmaceutical composition containing tricyclic compound for treating or preventing sleep disorders
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
WO1997032871A1 (en) * 1996-03-08 1997-09-12 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
JP4242940B2 (ja) 1997-02-13 2009-03-25 高砂香料工業株式会社 光学活性アミン誘導体の製造法
JP4081161B2 (ja) * 1997-09-05 2008-04-23 武田薬品工業株式会社 光学活性化合物の製造法
US6348485B1 (en) * 1998-06-09 2002-02-19 Takeda Chemical Industries, Ltd. Method for treating or preventing sleep disorders
JP3509637B2 (ja) * 1998-06-09 2004-03-22 武田薬品工業株式会社 睡眠障害予防治療剤
AU2002214305A1 (en) * 2000-11-17 2002-05-27 Takeda Chemical Industries Ltd. Pharmaceutical preparation containing copolyvidone
JP3633895B2 (ja) * 2000-11-17 2005-03-30 武田薬品工業株式会社 コポリビドン含有製剤

Also Published As

Publication number Publication date
EP1792899A1 (en) 2007-06-06
NZ553562A (en) 2010-08-27
GT200500257A (es) 2006-04-17
IL181462A (en) 2011-12-29
MY158073A (en) 2016-08-30
ECSP077317A (es) 2007-04-26
US20130079397A1 (en) 2013-03-28
KR101298335B1 (ko) 2013-08-20
MY147822A (en) 2013-01-31
KR20070054200A (ko) 2007-05-28
CN102516211A (zh) 2012-06-27
AU2005283521B2 (en) 2011-10-13
CA2764314A1 (en) 2006-03-23
JP5615304B2 (ja) 2014-10-29
EP1792899A4 (en) 2009-12-16
SA05260347A (ar) 2005-12-03
PA8645701A1 (es) 2006-09-22
CA2579121C (en) 2013-07-30
GT200500257AA (es) 2008-07-28
CN101056867B (zh) 2011-12-07
CN101056867A (zh) 2007-10-17
EP1792899B1 (en) 2014-07-09
CA2579121A1 (en) 2006-03-23
ES2485890T3 (es) 2014-08-14
PE20130154A1 (es) 2013-02-27
US20140066499A1 (en) 2014-03-06
CA2764314C (en) 2014-06-17
GEP20094725B (en) 2009-07-10
AU2005283521A1 (en) 2006-03-23
MA28855B1 (fr) 2007-09-03
UA95598C2 (ru) 2011-08-25
US20090036521A1 (en) 2009-02-05
MX2007002822A (es) 2007-04-23
NO20071866L (no) 2007-05-29
HN2005000548A (es) 2007-04-20
PE20081390A1 (es) 2008-10-24
PH12012501172A1 (en) 2014-04-28
IL181462A0 (en) 2007-07-04
CR8975A (es) 2007-08-28
JPWO2006030739A1 (ja) 2008-05-15
TWI400220B (zh) 2013-07-01
IL207510A (en) 2013-02-28
BRPI0515170A (pt) 2008-07-08
TW200613239A (en) 2006-05-01
US8097737B2 (en) 2012-01-17
PE20060662A1 (es) 2006-08-22
ZA200701724B (en) 2008-08-27
WO2006030739A1 (ja) 2006-03-23
JP5127228B2 (ja) 2013-01-23
SG151330A1 (en) 2009-04-30
UY29118A1 (es) 2006-06-30
JP2012116848A (ja) 2012-06-21
RU2385318C2 (ru) 2010-03-27
EP2537842A1 (en) 2012-12-26
AR050737A1 (es) 2006-11-15
US20120088826A1 (en) 2012-04-12
US8609871B2 (en) 2013-12-17
RU2007113811A (ru) 2008-10-20

Similar Documents

Publication Publication Date Title
CR8975A (es) Proceso para la produccion de derivados de amina opticamente activos
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
EA200600621A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
MX340573B (es) Proceso para la fabricacion de compuestos farmaceuticamente activos.
BR0107425A (pt) Processo para a preparação compostos de derivados de ácido 3-hidróxi picolìnico e uso dos compostos
MX2009013565A (es) Derivados de azapeptidos.
DK1987152T3 (da) Fremgangsmåde til fremstilling af optisk aktive chirale aminer
SG170794A1 (en) Process for preparation of hiv protease inhibitors
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
WO2010076810A3 (en) A process for the preparation of gefitinib
BRPI0515081A (pt) derivados de fenilaminopirimidina como inibidores de bcr-abl cinase
PL379543A1 (pl) Wytwarzanie pochodnych 1,3-difenyloprop-2-en-1-onu
UY32034A (es) Nuevo procedimiento de resolución de enantiómeros de (3,4-dimetoxi-biciclo[4.2.0]octa-1,3,5-trien-7-il)nitrilo y aplicación en la sistesis de ivabradina
MX2009000480A (es) Bencilaminas, un proceso para su produccion y su uso como agentes antiinflamatorios.
AR050518A1 (es) Proceso de amonolisis para la preparacion de intermedarios para inhibidores de dpp iv
CY1116721T1 (el) Νεες ενωσεις ως προσδεματα υποδοχεων ισταμινης η3
EA200801893A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве ингибиторов воспаления
EA200600605A1 (ru) Перегруппированные пентанолы, способ их получения и их применение в качестве противовоспалительных средств
SE0403085D0 (sv) Novel componds
MX2010009876A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexanocarboxilico por medio del derivado de ciclohexanocarboxamida correspondiente.
BRPI0808570B8 (pt) processo para a preparação de inibidores de glyt-1
MX2010001961A (es) Procedimiento para la preparacion de derivados de 2,2-difluoroetilamina mediante hidrogenacion de amida.
MA28144A1 (fr) Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables
TR200402720T4 (tr) Metalloproteaz inhibitörleri olarak 2-(4-piridinil)-benzofüran'lar